All In Biotech

NDA 050789 · Fresenius Kabi USA

Tobramycin Sulfate

Tobramycin Sulfate · Injection

Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Jul 13, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

12,545

10,114 serious, 1,303 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: NEPHROTOXICITY, OTOTOXICITY AND EMBRYO-FETAL TOXICITY WARNING: NEPHROTOXICITY, OTOTOXICITY, NEURO MUSCULAR BLOCKADE AND FETAL HARM See full prescribing information for complete boxed warning. Nephrotoxicity Tobramycin for Injection may cause acute kidney injury. Monitor renal function and serum tobramycin concentrations in all patients. Reduce the dose or discontinue the Tobramycin for Injection if renal impairment occurs. ( 5.1 ) Ototoxicity Tobramycin for Injection may cause irreversible auditory and vestibular toxicity. Monitor for symptoms of ototoxicity, and for renal function and serum tobramycin levels in all patients. Reduce the dose or discontinue the Tobramycin for Injection if impairment of renal function occurs. Discontinue Tobramycin for Injection if ototoxicity occurs. ( 5.2 ) Neuromuscular Blockade Aminoglycosides have been associated with neuromuscular blockade....

What it is approved for

From the label in effect Feb 7, 2024.

Tobramycin for Injection, is an aminoglycoside antibacterial indicated for the treatment of serious bacterial infections caused by susceptible isolates of the designated bacteria in the diseases listed below ( 1.1 ): Septicemia in the pediatric patient and adults caused by P. aeruginosa , E. coli , and Klebsiella species (spp). Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp., and Enterobacter spp. Skin, bone, and skin structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp., Enterobacter spp., and S. aureus. Complicated urinary tract infections caused by P. aeruginosa , Proteus spp., (indole-positive and indole-negative), E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., S. aureus , Providencia spp., and Citrobacter spp. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin for Injection and other antibacterial drugs, Tobramycin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.2 ). 1.1 Septicemia Tobramycin for Injection is indicated for the treatment of septicemia caused by susceptible isolates of P. aeruginosa, E. coli, and Klebsiella spp., in adult and pediatric patients. 1.2 Lower Respiratory Tract Infections Tobramycin for Injection is indicated for the treatment of lower respiratory tract infections caused by susceptible isolates of P. aeruginosa, Klebsiella spp., Enterobacter spp., Serratia spp., E. coli, and S. aureus in adult and pediatric...

Mechanism: Tobramycin sulfate is an aminoglycoside antibacterial drug [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 2004 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
1 products under this application
  • TOBRAMYCIN SULFATE · TOBRAMYCIN SULFATE EQ 1.2GM BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pneumonia782
  • off label use778
  • drug ineffective710
  • acute kidney injury690
  • dyspnoea688
  • infective pulmonary exacerbation of cystic fibrosis624
  • death482
  • infection465
  • hospitalisation462
  • cough458
  • condition aggravated451
  • cystic fibrosis430

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200486
2005104
200683
2007133
200898
2009104
2010114
2011213
2012207
2013171
2014283
2015449
2016506
2017561
20181,032
20191,557
20201,399
20211,030
2022981
2023832
20241,035
2025894
2026673

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tobramycin Sulfate (Tobramycin Sulfate)

2024 spending

$7.3M

Beneficiaries

5,660

12,737 claims

Per beneficiary

$1,298

$6.98 per unit

View as table
YearSpending
2020$17,541,571
2021$8,011,124
2022$2,105,371
2023$1,953,192
2024$7,343,974

Part B: Tobramycin Sulfate (Tobramycin Sulfate) · HCPCS J3260

2024 spending

$68K

Beneficiaries

7,168

12,247 claims

Per beneficiary

$9

2024 ASP limit $2.47 per unit

View as table
YearSpending
2020$56,438
2021$66,503
2022$61,825
2023$55,228
2024$67,742

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 791 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.